JNJ's SNDA For Spravato Monotherapy Gets FDA Approval For Treatment-Resistant Depression
Tuesday announced that the U.S. Food and Drug Administration has approved supplemental New Drug Application or sNDA for Spravato, a monotherapy for adults with treatment-resistant depression, a psychiatric disorder.
One commenter wrote about Leo and his treat: "I love the slow start THEN it hits the brain he's going full speed lol." ...
Lives are being lost and families torn apart because of "woefully inadequate care" for people with eating disorders, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback